Business
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)-- Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted
About this update from Immunome, Inc.
[{"type":"text","content":" BOTHELL, Wash.--(BUSINESS WIRE)--\nImmunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 10:30 a.m. PST.\n\n\nInterested parties can access a live audio webcast of the presentation via the Investor Relations section of Immunome’s website at www.immunome.com. A replay webcast will be available for approximately 30 days following the live presentation.\n\n\nAbout Immunome, Inc.\n\n\nImmunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugate therapies. Our pipeline includes varegacestat, a late-clinical stage GSI; IM-1021, a clinical-stage ROR1 ADC; and IM-3050, a FAP-targeted radiotherapy that recently received IND clearance. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. For more information, visit www.immunome.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20260106254447/en/\n\nInvestor Contact\nMax Rosett\nChief Financial Officer\[email protected]\n\n\nSource: Immunome, Inc.","length":3303,"tagName":"div"}]